We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+11.13%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.52B
AUM Growth
-$86M
Cap. Flow
-$267M
Cap. Flow %
-17.65%
Top 10 Hldgs %
55.26%
Holding
50
New
2
Increased
13
Reduced
10
Closed
3

Top Buys

Rank Stock Value
1
LNZA icon
LanzaTech
LNZA
+$106M
2
FDMT icon
4D Molecular Therapeutics
FDMT
+$13.6M
3
INSM icon
Insmed
INSM
+$9.7M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$6.72M
5
VERV
Verve Therapeutics
VERV
+$5.66M

Top Sells

Rank Stock Value
1
SYK icon
Stryker
SYK
+$195M
2
STE icon
Steris
STE
+$86.4M
3
BSX icon
Boston Scientific
BSX
+$62.6M
4
CTLT
CATALENT, INC.
CTLT
+$49.4M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 57.28%
2 Technology 25.52%
3 Financials 5.42%
4 Communication Services 4.36%
5 Industrials 4.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERV
26
DELISTED
Verve Therapeutics
VERV
$17.3M 1.14%
1,200,000
+288,889
+32% +$5.66M
DICE
27
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$16.7M 1.1%
536,100
+71,100
+15% +$2.11M
RCKT icon
28
Rocket Pharmaceuticals
RCKT
$394M
$15.8M 1.04%
920,000
+70,000
+8% +$1.37M
BLU
29
DELISTED
BELLUS Health Inc.
BLU
$15.4M 1.02%
2,137,975
+439,891
+26% +$3.41M
SPRB
30
Spruce Biosciences
SPRB
$129M
$14.9M 0.98%
89,631
+29,440
+49% +$5.47M
INSP icon
31
Inspire Medical Systems
INSP
$1.74B
$14M 0.93%
60,000
-3,304
-5% -$835K
TMCI icon
32
Treace Medical Concepts
TMCI
$309M
$13.6M 0.9%
540,000
-97,317
-15% -$2.28M
RLYB icon
33
Rallybio
RLYB
$85.8M
$13M 0.86%
283,764
-3,237
-1% -$167K
FDMT icon
34
4D Molecular Therapeutics
FDMT
$562M
$12M 0.79%
+700,000
New +$13.6M
NARI
35
DELISTED
Inari Medical, Inc. Common Stock
NARI
$11.1M 0.73%
180,000
-60,800
-25% -$3.65M
SILK
36
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$10.8M 0.71%
275,511
– –
PHVS icon
37
Pharvaris
PHVS
$2.44B
$10.7M 0.71%
1,329,325
+142,018
+12% +$1.25M
ABCL icon
38
AbCellera Biologics
ABCL
$2.12B
$8.5M 0.56%
1,126,915
– –
GRTX
39
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$6.3M 0.42%
2,459,021
– –
IOBT
40
DELISTED
IO Biotech
IOBT
$6.15M 0.41%
3,277,932
– –
LUNG icon
41
Pulmonx
LUNG
$87.6M
$5.71M 0.38%
510,555
– –
KNTE
42
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$5.1M 0.34%
815,707
– –
LVTX
43
DELISTED
LAVA Therapeutics
LVTX
$5.1M 0.34%
3,070,558
-256,754
-8% -$719K
DMRA
44
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$4.97M 0.33%
99,912
– –
MQ icon
45
Marqeta
MQ
$1.66B
$2.02M 0.13%
110,390
– –
KZR
46
DELISTED
Kezar Life Sciences
KZR
$1.46M 0.1%
46,560
-70,940
-60% -$4.1M
SPRO icon
47
Spero Therapeutics
SPRO
$73M
$680K 0.04%
468,902
– –
BSX icon
48
Boston Scientific
BSX
$71.5B
– –
-1,353,081
Closed -$62.6M
STE icon
49
Steris
STE
$23.1B
– –
-467,687
Closed -$86.4M
SYK icon
50
Stryker
SYK
$130B
– –
-796,941
Closed -$195M
1
2

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q1 2023 Portfolio in Review

As of Q1 2023, Novo Holdings A/S held 50 positions worth $1.52B, down 5.4% from $1.6B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Novo Holdings A/S withdrew a net $267M in Q1 2023, closing 3 positions and reducing 10 holdings. Its most notable exit was Stryker, an estimated $195M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 70% a quarter earlier, followed by Technology and Financials.

Against the trend, Novo Holdings A/S opened a new position in LanzaTech worth $61.4M.

  • Novo Holdings A/S's largest Q1 2023 buy was LanzaTech: 158,148 shares worth $61.4M.
  • Novo Holdings A/S added most to Insmed in Q1 2023, an estimated $9.7M increase.
  • Novo Holdings A/S's biggest Q1 2023 reduction was CATALENT, INC., cutting an estimated $49.4M.
  • Novo Holdings A/S fully exited Stryker in Q1 2023, selling an estimated $195M.
  • Novo Holdings A/S's ten largest holdings make up 55% of its $1.52B portfolio in Q1 2023.
  • Novo Holdings A/S opened 2 new positions and closed 3 in Q1 2023.
  • Novo Holdings A/S's portfolio value fell 5.4% quarter-over-quarter to $1.52B.

Based on Novo Holdings A/S's 13F filing for Q1 2023, filed 15 May 2023.